ABSTRACT
Objective: To investigate an optimal chemotherapy regimen for patients diagnosed with lung adenocarcinoma harboring common EGFR mutations. Methods: Clinical data of 4,021 patients diagnosed with advanced primary lung adenocarcinoma who were admitted to Guangdong Lung Cancer Institute from June 2007 to June 2014 were retrospectively collected. The efficacy of the standard chemotherapy regimen in patients diagnosed with luny adenocarcinoma harboring common EGFR mutations was analyzed. Results: In total, 205 patients were included in the study, and 119, 60 and 81 patients received gemcitabine plus platinum, pemetrexed plus platinum, and paclitaxel plus platinum regimens, respectively. Statistical difference was not observed in the objective response rate (ORR,25.2%, 25.0%, 30.8%, respectively) and progression free survival (PFS, 5.5, 5.2, 6.2 months, respectively) between these three treatment regimens (P=0.979, P=0.811). Conclusions: Platinum-based chemotherapy regimens based on gemcitabine, pemetrexed, and paclitaxel have similar efficacy in patients diagnosed with advanced primary lung adenocarcinoma harboring common EGFR mutations.